| Project/Area Number |
09671401
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
HAYASHI Akihiko Kurume Univ., Sch., Med., Dep. Surg., Lecturer, 医学部, 講師 (70180958)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ITOH Kyogo Kurume Univ., Sch. Med., Dep. Immunol, Professor, 医学部, 教授 (50125499)
GOMI Shinnya Kurume Univ., Sch., Med., Dep. Immunol., Res. Associa, 医学部, 助手 (30289368)
|
|---|
| Project Period (FY) |
1997 – 1999
|
| Project Status |
Completed (Fiscal Year 1999)
|
| Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 1999: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1998: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1997: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Keywords | Lung cancer / Tumor-rejection / Gene / Cancer Vaccine / HLA-class I / Peptide antigen / Specific immunotherapy / HLA-A24 |
|---|
| Research Abstract |
A main objective of this research project is to identity tumor rejection antigens of lung cancers that were recognized by HLA-class I-restricted cytotoxic T lymphocytes (CTLs). We have identified four tumor-rejection antigens (SART3, cyclophilin B, ART1 and ART4) that were recognized by HLA-A24-restricted CTLs. The three (SART-3, ART-1 and ART-4) tumor rejective antigens were newly identified molecules, while the remaining one (cyclophilin B) was a known molecule. These tumor rejection antigens were broadly expressed in the majority of lung cancers. Peptide antigens recognized by these CTLs, and those capable of inducing HLA-class I restricted CTLs from peripheral blood mononuclear cells (PBMCs) of lung cancer patients were also identified in these tumor-rejection antigens. Some of these peptides (Cyclophilin BィイD284-92ィエD2, Cyclophilin BィイD291-99ィエD2) are currently used for phase I clinical studies as cancer vaccines in HLA-A24ィイD1+ィエD1 lung cancer patients in our Kurume University Hospital. These basic and clinical research shall provide new insight for better understanding of molecular basis of T cell-mediated recognition of cancer cells. Further, these studies may open the door of specific immunotherapy of lung cancers.
|
